Basic Information
CanBas is a biopharmaceutical company engaged in the research and development of anti-cancer drugs. The company has developed CBP501 and completed Phase II clinical trials for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. It has also developed CBS9106, a reversible XPO-1 inhibitor for the treatment of solid tumors.
Canbas Co.,Ltd.
Shizuoka,Shizuoka,Japan
15~50 people
January 18, 2000
--